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A B S T R A C T
To investigate rates and outcomes of antibiotic de-escalation during pre-engraftment neutropenia in alloge-
neic hematopoietic stem cell transplantation (HSCT) recipients. 110 consecutive HSCTs performed between
January 2013 and March 2014 were analyzed. De-escalation was deﬁned as narrowing the spectrum of an-
tibiotic treatment either within (early) or after 96 hours (late) from starting antibiotics. Discontinuation,
considered a form of de-escalation, was deﬁned as stopping antibiotics before engraftment. De-escalation failure
was deﬁned as restarting/escalating antibiotics within 96 hours after de-escalation. Predictors of de-
escalation were analyzed. Among 102 patients who started antibiotics and were included, 68 (67%) received
monotherapy (mainly piperacillin-tazobactam, n = 58), whereas 34 (33%) received combination therapy (mainly
meropenem plus glycopeptide, n = 24). Median duration of neutropenia was 17 days. Bloodstream infections
(BSIs) were diagnosed in 28 patients (20%). Early de-escalation rate was 25.5% (n = 26) and mostly consisted
of reducing the spectrum of β-lactams (n = 11, 42%). In comparison with theoretical scenario of continuing
therapy until engraftment, the median savings in terms of antibiotic days were 10 for meropenem, 8 for
piperacillin-tazobactam, and 7 for vancomycin. Failure rate of early de-escalation was 15% (4/26). Late de-
escalation rate was 30.4% (n = 31) and failure rate 19% (6/31). The rate of de-escalation any time before
engraftment was 55.9% (n = 57), including discontinuation in 33 patients (32%). Death at day 60 after HSCT
occurred in 3 patients who never underwent de-escalation. Acute myeloid disease and BSIs were indepen-
dent predictors of early de-escalation. De-escalation, including discontinuation, is feasible and safe in pre-
engraftment neutropenia after allogeneic HSCT.
© 2018 American Society for Blood and Marrow Transplantation.
INTRODUCTION
The worldwide emergence of multidrug-resistant (MDR)
bacteria is an alarming phenomenon burdened by increased
mortality rates [1], with ﬁgures up to 46% and 42% among
patients with hematologic malignancies in cases of
carbapenem-resistant Klebsiella pneumoniae and MDR Pseu-
domonas aeruginosa, respectively [2]. Hematopoietic stem cell
transplantation (HSCT) recipients, with their prolonged neu-
tropenia and previous exposure to multiple antibiotic
therapies, represent a population at high risk for adverse out-
comes in case of MDR bacteria infections [3].
Counteracting the spread of MDR bacteria requires effec-
tive application of infection control protocols and the judicious
prescription of antibiotics within dedicated stewardship pro-
grams [4]. Hence, several strategies have been developed,
including the de-escalation approach proposed by the Fourth
European Conference on Infection in Leukemia. This ap-
proach consists of prompt administration of a broad-spectrum
treatment as soon as infection is suspected and subsequent
streamlining within 96 hours [5]. A de-escalation strategy
allows the best possible coverage of resistant pathogens im-
mediately at the onset of signs and symptoms and subsequent
reduction of selective pressure on bacteria through narrow-
ing the spectrum if resistant bacteria are not isolated.
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Data regarding the rates and outcomes of de-escalation
strategy are mostly provided by observational studies, and
only 4 randomized clinical trials have been conducted to date
[6-9]. Almost all studies have been performed in intensive
care units (ICUs), and deﬁnitions and timing of de-escalation
varied signiﬁcantly [10]. In addition, only few studies and 1
recent randomized trial have focused on neutropenic cancer
patients [9,11-14], but very limited data are currently avail-
able on the pre-engraftment period in HSCT. The safety of
discontinuation of empirical treatment before the resolu-
tion of neutropenia has also been a source of debate [15,16].
The purpose of this study was to report the rates and out-
comes of de-escalation (including discontinuation) during the
pre-engraftment phase of allogeneic HSCT in patients with
fever or infection and neutropenia.
METHODS
Patients
A retrospective observational study based on a prospective database was
conducted at the Hematology Division of Ospedale Policlinico San Martino
(Genoa, Italy). All patients receiving allogeneic HSCT between January 2013
and March 2014 were included.
Transplant Procedures
Donor choice, conditioning regimen, and graft-versus-host disease pro-
phylaxis were performed according to local standard procedures [17,18].
Unmanipulated bone marrow was used as a stem cell source for related
donors. In case of haploidentical donors, graft-versus-host disease prophy-
laxis consisted of cyclophosphamide 50mg/kg on days +3 and +5, cyclosporine
A until day +180, and mycophenolate mofetil from days +1 to +28 [19,20].
All patients received levoﬂoxacin prophylaxis from the onset of condi-
tioning until engraftment. Based on local epidemiology [21], ﬁrst-line
antibiotic treatment during neutropeniawas piperacillin-tazobactam, whereas
patients with severe clinical presentation or colonization and previous in-
fection due to extended-spectrum β-lactamase–producing bacteria received
meropenem.Methicillin-resistant Staphylococcus aureus (MRSA) coverage was
added according to international guidelines [5,22].
Deﬁnitions
Neutropenia was deﬁned as a granulocyte count < 500 cells/mm3 and
the engraftment date as the ﬁrst of 3 consecutive days with neutrophils above
500 cell/mm3 [3]. In case of nonengraftment, the follow-up was consid-
ered until day +60 after transplant or the day of second transplant, whichever
occurred ﬁrst.
Since 2012, a de-escalation strategy has been introduced in our center
as a part of antimicrobial stewardship, with particular emphasis on pre-
venting the selection of carbapenem-resistant strains [23]. De-escalation of
empiric antibiotic treatment was deﬁned as switching to a narrower spec-
trum β-lactam or stopping any antibiotic. Discontinuation, deﬁned as stopping
empirical therapy and resuming ﬂuoroquinolone (FQ) prophylaxis at any time
before the engraftment, was considered a form of de-escalation. Failure of
de-escalation (including discontinuation) was deﬁned as escalating/
restarting antibiotic therapy, having a BSI, or fever recurrence within 96 hours
from de-escalation/discontinuation.
Endpoints
The primary endpoint was the rate of early de-escalation, within 96 hours
from the onset of the ﬁrst antibiotic treatment, in agreement with recom-
mendations [5]. Secondary endpoints were the rates of late de-escalation
(after 96 hours of the antibiotic treatment), de-escalation occurring any time
before engraftment, the number of days of antibiotic therapy saved by de-
escalation, and outcomes (failure and survival at day +60).
Because traditionally empirical antibiotic therapy is stopped on the day
of neutropenia resolution, the beneﬁt in terms of saving days of antibiotic
exposure through de-escalation was evaluated. Brieﬂy, it was calculated by
counting the number of days from the day of de-escalation to the day of
the resolution of neutropenia, which in the theoretical scenario of continu-
ing empirical therapy unmodiﬁed until engraftment would be the additional
length of antibiotic administration. Factors associatedwith de-escalationwere
also investigated.
Statistical Analyses
The differences between the groups (de-escalation yes versus no) were
assessed by means of the chi-square test or Fisher’s exact test when appro-
priate for categorical variables and with Mann-Whitney test for continuous
variables. Continuous variables were reported as median values with range.
A backward multivariate logistic regression analysis included all variables
associated in the univariate analysis with a P < .2. The analyses were per-
formed using SPSS version 21.0 (IBM Corp., Armonk, NY), and P ≤ .05 was
considered statistically signiﬁcant.
RESULTS
Patients and Infections
Overall, 110 consecutive HSCT recipients received trans-
plant during the study period, and their characteristics are
reported in Table 1. Acute myeloid diseases (acute myelog-
enous leukemia or myelodysplastic syndrome) were the most
frequent underlying disease (n = 52, 47%), whereas the most
frequent donor was haploidentical (n = 76, 69%). The median
length of neutropenia was 17 days in those who engrafted
(range, 10 to 29); 6 patients did not reach engraftment (6%),
and 3 of them received a second HSCT. The overall survival
rate at day 60 post-HSCT was 97%.
Among 110 patients transplanted during the observa-
tion period, 8 patients (7%) did not receive antibiotic treatment
and were not included in the study. The remaining 102 pa-
tients started antibiotic treatment because of fever (n = 100,
98%) or skin lesions suggesting bacterial infections (n = 2, 2%).
The ﬁrst episode of suspected or documented infection
was treated with monotherapy in 68 patients (67%), divided
Table 1
Population Characteristics of 102 Patients Included in the Analyses
Baseline variables No. of Patients (%)
Gender
Male 61 (59.8)
Female 41 (40.2)
Median age, yr (range) 48 (18-69)
Underlying disease
Acute myeloid leukemia 52 (47)
Acute lymphoproliferative 25 (23)
Chronic lymphoproliferative 18 (16)
Chronic myeloproliferative 14 (13)
Aplastic anemia 1 (1)
Status of the underlying disease at transplant
In remission 72 (65.5)
Active 38 (34.5)
Year of HSCT
2013 91 (82.7)
2014 19 (17.3)
Donor type
Matched related 21 (19)
MUD/MMR 13 (12)
Haploidentical* 76 (69)
Conditioning
Myeloablative 59 (54)
Reduced intensity 51 (46)
Outcome variables
Febrile episodes
None 10 (9)
1 59 (54)
2 29 (26)
≥ 3 12 (11)
BSIs
None 82 (74.5%)
1† 20 (18.2%)
≥ 2‡ 8 (7.3%)
MUD indicates matched unrelated donor; MMR, mismatched related.
* In case of haploidentical donor, prophylaxis of graft-versus-host disease
included of 2 doses of post-transplant cyclophosphamide.
† Causative pathogens: E. coli in 8, methicillin-resistant Staphylococcus
epidermidis (MRSE) in 5, S. aureus and Streptococcus mitis in 2 each, Pseu-
domonas spp., and Enterococcus faecium and Enterobacter cloacae in 1 each.
‡ Causative pathogens: 2 episodes due to E. coli; 2 episodes due to E.
faecium, E. coli and MRSE, E. coli and E. faecium, MRSE and E. faecium, Pseu-
domonas aeruginosa and E. faecium, P. aeruginosa and S. viridans, E. coli and
MRSE, and Candida.
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as follows: piperacillin-tazobactam (n = 58, 57%), meropenem
(n = 5, 5%), ceftazidime (n = 2, 2%), and vancomycin for docu-
mented gram-positive infection (n = 3, 3%). Drug combinations
were prescribed as ﬁrst-line treatment in 34 patients (33%)
and included meropenem plus MRSA coverage (n = 24, 23%),
piperacillin-tazobactam plus MRSA coverage (n = 9, 9%), and
meropenem plus daptomycin and amikacin (n = 1, 1%).
BSIs occurred in 28 patients (27%), and 8 patients (8%) had
more than 1 episode. Among 37 isolated pathogens, the most
frequent were Escherichia coli (n = 12, 32%), staphylococci
(n = 11, 30%), and enterococci (n = 6, 16%).
Early De-Escalation
Early de-escalation rate was 25.5% (n = 26) and con-
sisted of reducing the spectrum of gram-negative coverage
in 11 patients (42%), discontinuing MRSA coverage in 6 pa-
tients (23%), both reducing the spectrum of gram-negative
coverage and discontinuingMRSA coverage in 6 patients (23%),
discontinuing piperacillin-tazobactam and resuming FQ pro-
phylaxis in 2 patients (8%), and discontinuing aminoglycoside
in 1 patient (4%). Later, 8 patients in the early de-escalation
group discontinued the empirical therapy to FQ prophylax-
is. The changes in antibiotic therapy and the main outcomes
in different groups are outlined in Figure 1.
The failure of early de-escalation occurred in 4 patients
(15.4%, 4/26), being in fever recurrence in 1, bartholinitis in
1, BSI due to a coagulase-negative staphylococcus in 1, and
BSI due to extended-spectrum β-lactamase–producing E. coli
in 1. These BSIs were not recurrences of previous infec-
tions. All failures were successfully treated with escalation
of antibiotic therapy. No deaths were recorded in the early
de-escalation group. Of note, the occurrence of a second
episode of fever or infection any time before engraftment was
similar (30.7% [8/26] versus 31.2% [23/76]) in those who did
and did not undergo early de-escalation (the second group
includes patients undergoing late de-escalation).
Compared with a theoretical scenario of continuing em-
pirical therapy unmodiﬁed until engraftment, early de-
escalation resulted in saving of a median of 10 days of
meropenem (range, 1 to 28), 8 days of piperacillin-tazobactam
(range, 2 to 17), and 7 days of vancomycin/anti-MRSA cov-
erage (range, 1 to 21). Considering the group of 74 patients
without BSI, failure of early de-escalation occurred in 5 of 11
patients (45.5%; all responded well to antibiotic escalation)
versus second episode of fever occurring in 17 among 63 who
did not perform early de-escalation (27%).
Late De-Escalation
Late de-escalation rate was 30.4% (n = 31). It could be
divided into reducing the spectrum of antibiotics (n = 9, 9%;
stopping MRSA coverage in 7 and reducing the spectrum of
gram-negative coverage in 2) and into direct discontinuation
Figure 1. Summary of main results.
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to FQ prophylaxis (n = 22, 22%) after a median of 10 days of
antibiotic therapy (range, 4 to 22).
The failure of late de-escalation was registered in 6 of 31
patients (19%). It occurred after reducing the spectrum in 1
patient who developed subsequently a BSI due to Pseudo-
monas putida (11%, 1/9) and after direct discontinuation to
FQs in 5 patients (23%, 5/22; fever recurrence n = 4, BSI due
to Enterococcus faecium, n = 1). Additionally, 1 patient expe-
rienced a BSI due to coagulase-negative staphylococcus and
restarted vancomycin 6 days after de-escalation while still
on treatment with meropenem for P. aeruginosa sepsis, and
another patient restartedmeropenem and vancomycin 14 days
after the discontinuation to FQs. Considering the group of 74
patients without BSI, failure of late de-escalation occurred
in 2 of 27 patients (7%) versus subsequent episode of fever
occurring in 10 among 36 who did not perform de-escalation
(28%).
De-Escalation Any Time before Engraftment and Outcome
Overall de-escalation rate (early and late) was 55.9%
(n = 57) and was performed according to the results of a pos-
itive blood culture in 19 patients (33%) and without any
isolated bacteria in 38 cases (67%). All BSIs occurring as fail-
ures were new episodes and not recurrences of previous
infections. Failures of early or late de-escalation occurred in
10 patients (17.5%), with no cases of septic shock or death,
and were successfully treated with antibiotics. Additionally,
2 patients modiﬁed antibiotic therapy more than 96 hours
after late de-escalation (as reported above), whereas the
remaining 45 patients (79%) did not have further infection
episodes and did not modify the antibiotic therapy. Among
those in whom discontinuation was performed, FQs prophy-
laxis was resumed for a median of 3 days (range, 1 to 17).
Nonengraftment occurred in 3 patients from the early de-
escalation group and in 3 among those who never de-
escalated. Death at 60 days after HSCT occurred only in 3
patients in whom de-escalation was never performed.
Predictors of De-Escalation
In univariate analyses early de-escalation was more fre-
quent in patients with acute myeloid disease (P = .006), in
those having ≥2 febrile episodes (P = .01), and in those having
a BSI (P = .001), whereas de-escalation anytime was more fre-
quent only in patients with acute myeloid disease (P = .007).
The multivariate analyses conﬁrmed that factors associated
with early de-escalation were acute myeloid disease (P = .019)
and presence of BSI (P < .0001), whereas acutemyeloid disease
was the only factor associated with de-escalation any time
(P = .019) (Table 2).
DISCUSSION
This retrospective study showed that de-escalation and
discontinuation of antibiotic treatment are feasible in the pre-
engraftment phase of allogeneic HSCT, with failures
responding well to restarting antibiotic therapy and similar
rates of fever relapses or mortality compared with the non–
de-escalation group. Early de-escalation was performed in
one-fourth of patients. To the best of our knowledge, no data
Table 2
Factors Associated with De-Escalation at 96-Hour or De-Escalation at Any Time Before Engraftment in Univariate and Multivariate Analysis
De-Escalation 96 Hours
(n = 26/102 [25.5%])
P De-Escalation Any Time
Before Engraftment
(n = 57/102 [55.9%])
P
Univariate analysis
Age, yr (median 48 yr) (range) 49 (25-60) .594 49 (21-69) .492
Sex, n (%) .799 .658
Male 15 (24.6) 33 (54.1)
Female 11 (26.8) 24 (58.5)
Diagnosis, n (%) .006 .007
Acute myeloid disease 18 (38.3) 33 (70.2)
Others 8 (14.5) 24 (43.6)
Disease status at HSCT, n (%) .12 .6
In remission 13 (20.3) 37 (57.8)
Active 13 (34.2) 20 (52.6)
Donor type, n (%) .67 .59
Matched related 5 (27.8) 12 (66.7)
MUD/MMR 2 (15.4) 7 (53.8)
Haploidentical 19 (26.8) 38 (53.5)
Conditioning, n (%) .21 .39
Myeloablative 11 (20.4) 28 (51.8)
Reduced intensity 15 (31.3) 29 (60.4)
Neutropenia duration, days
(median 17 days) (range)
17 (11-43) .456 17 (11-43) .096
Fever episodes, n (%) .01 .39
≤1 10 (16.4) 32 (52.5)
≥2 16 (39.0) 25 (61.0)
BSIs, n (%) .001 .134
Yes 15 (53.6) 19 (67.9)
No 11 (14.9) 38 (46.3)
Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Multivariate analysis
Diagnosis
Acute myeloid disease 1.00 .019 1.00 .008
Others .291 (.105-.817) .328 (.144-.747)
BSIs
No 1.00 <.0001
Yes 6.291 (2.270-17.434)
CI indicates conﬁdence interval.
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are available for comparison of such an early de-escalation,
except for a study of septic cancer patients that showed a de-
escalation rate of 58% within 5 days from ICU admission.
However, only 21% of these patients were neutropenic on the
ﬁrst day of treatment, and, more importantly, the median
number of antibiotics at ICU admission was 3, which made
it easier to de-escalate some of them [11].
In the era of increasing antimicrobial resistance, the saving
of days of antibiotic exposure is extremely important, not only
from the global epidemiologic point of view but also from
the perspective of the individual patients. In our study, in the
26 patients in whom early de-escalation was performed, a
median 10 days of meropenem were saved, which consti-
tutes an important carbapenem-saving approach. Additionally,
savings in terms of exposure to glycopeptides and
ureidopenicillin were also noted. It is unsurprising that early
de-escalation in patients without BSIs might be followed by
subsequent new fever episodes (45.5% in our cohort of pa-
tients with a median of 17 days of neutropenia), also because
patients with BSIs continue at least 1 antibiotic for 10 days.
However, all of them responded to antibiotic escalation, no
BSI-related death occurred, and the possibility of reusing ﬁrst-
line antibiotic therapy was preserved.
The overall pre-engraftment de-escalation rate in our study
was 55.9%, which represents the highest percentage so far
demonstrated in a cohort of exclusively neutropenic pa-
tients. Among the studies with similar populations, the
maximum de-escalation rate was 44%, reported by Mokart
et al. [12] in septic neutropenic patients in ICU. However, the
main differences, which limit the comparisonwith our cohort,
are the limited number of patients (30%, n = 30) who were
still neutropenic at the de-escalation of empirical treat-
ment and the fact that the deﬁnition of de-escalation included
also antifungal and antiviral drugs [12].
Despite a different setting, we demonstrated an overall de-
escalation rate that is consistent with that known for non-
neutropenic patients in 14 studies from ICUs (34% to 62%)
[10]. Even though patients in the ICU might be more fre-
quently hemodynamically unstable, neutropenic allogeneic
HSCT recipients are at particularly high risk of rapid clinical
deterioration and death in case of inadequate empirical treat-
ment [24,25].
None of the aforementioned studies on de-escalation con-
ducted in neutropenic patients was a randomized control trial
(RCT); thus, these results, which report similar mortality with
de-escalation approach, should be carefully interpreted as un-
derlined by a recent meta-analysis [26]. On the other hand,
it is extremely challenging to apply randomization criteria
to de-escalation strategy, because clinician judgment is a key
factor in selecting patients who might beneﬁt from this ap-
proach, and no objective algorithm has been validated. This
intrinsic bias of evaluating mortality stems from the fact that
less severely ill patients are de-escalated more frequently, as
outlined in some studies [11,12,27,28].
Feasibility and safety of antibiotic treatment discontinu-
ation in neutropenic patients, which is mildly endorsed by
2010 Infectious Diseases Society of America guidelines [22]
and recommended by Fourth European Conference on In-
fection in Leukemia [5], was an object of a recent RCT
performed in neutropenic patients [9]. It provided an excel-
lent demonstration that empirical antibiotic therapy
discontinued after 72 hours of apyrexia and clinical recov-
ery is safe and able to reduce unnecessary exposure to
antimicrobials [9]. Although our approach did not standard-
ize the time of discontinuation, it was performed in 32% of
patients, and none of patients who failed discontinuation and
needed to restart antibiotic therapy developed septic shock
or died. On the contrary, Micol et al. [16] prematurely inter-
rupted their study in neutropenic patients with acute myeloid
leukemia and fever of unknown origin because 3 of 7 pa-
tients demonstrated fever relapse within 3 days from
antibiotic discontinuation and 1 developed septic shock.
However, these results are in contrast with a retrospective
study in neutropenic patients and our experience, in which
19% and 17.5% of patients needed subsequent escalation of
antibiotics but no case of severe infection (severe sepsis or
shock) or death occurred [13]. More importantly, the recent
RCT on discontinuation also found no differences in the
number of days with fever, severe adverse event, or death
noted between the 2 study arms [9].
In our cohort the most important predictor of early de-
escalation was the diagnosis of BSI, which can be explained
by the fact that the presence of an isolated pathogen gives
a clinician a valid support to streamline the empirical treat-
ment. The fact that patients with acute myeloid disease were
more likely to undergo de-escalation might be explained by
the fact that infectious complications in this population
present frequently with clear clinical picture. In these pa-
tients more indolent viral or other opportunistic pathogens
might be less frequent than in patients with long pretransplant
history of chemotherapy and steroid treatment, as for example
in lymphoma or myeloma.
The limitations of this study include its retrospective nature
and limited number of patients. However, the data on anti-
biotic administration were collected from clinical charts
reporting speciﬁcally any changes in antibiotic treatment, and
this cohort included the largest number of neutropenic sub-
jects included in a de-escalation study. In addition, an
important aim of de-escalation strategy, which is the possi-
bility of inducing less resistance in patients’ microbiota and
avoiding selection of resistant bacteria already present, could
not be assessed, because this requires long-term observa-
tion periods. Finally, objective criteria in whom de-escalation
could be conﬁdently performed were not established; thus,
they may depend on physician’s expertise. In conclusion, in
a setting of prolonged neutropenia and severe immunosup-
pression, de-escalation and discontinuation strategies offer
the chance to reduce antibiotic exposure during pre-
engraftment neutropenia.
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